Stryker Co. (NYSE:SYK) Shares Sold by FORA Capital LLC

FORA Capital LLC reduced its stake in Stryker Co. (NYSE:SYK) by 85.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,482 shares of the medical technology company’s stock after selling 20,968 shares during the period. FORA Capital LLC’s holdings in Stryker were worth $1,258,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. FMR LLC lifted its stake in shares of Stryker by 3.0% in the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock worth $2,639,725,000 after acquiring an additional 215,782 shares during the period. Clearbridge Investments LLC raised its holdings in shares of Stryker by 2.9% in the 2nd quarter. Clearbridge Investments LLC now owns 2,323,452 shares of the medical technology company’s stock worth $790,554,000 after purchasing an additional 66,482 shares in the last quarter. Parnassus Investments LLC bought a new stake in shares of Stryker in the 3rd quarter worth approximately $762,798,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Stryker by 1.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,936,226 shares of the medical technology company’s stock worth $699,481,000 after purchasing an additional 37,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Stryker by 3.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,257,091 shares of the medical technology company’s stock worth $454,136,000 after purchasing an additional 47,322 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Down 0.4 %

Stryker stock opened at $388.14 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a market cap of $147.97 billion, a PE ratio of 41.60, a P/E/G ratio of 2.94 and a beta of 0.91. Stryker Co. has a twelve month low of $285.79 and a twelve month high of $398.20. The firm’s 50 day moving average price is $367.50 and its two-hundred day moving average price is $350.68.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.46 earnings per share. On average, research analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. UBS Group boosted their target price on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Canaccord Genuity Group boosted their target price on shares of Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Wells Fargo & Company boosted their target price on shares of Stryker from $381.00 to $405.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. Finally, StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $393.65.

Insiders Place Their Bets

In related news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 7,347 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. This represents a 42.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,781 shares of company stock valued at $24,612,275 over the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.